Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Who really owns JavaScript and why it’s a problem
This video breaks down the bizarre legal battle over who owns the JavaScript name. Despite not creating or maintaining the language, Oracle controls the trademark. The story traces how this happened ...
Sorry to burst your bubble right off the bat, but the show hasn’t even been renewed yet. While Welcome to Derry had a strong start, that number quickly fell off in subsequent episodes. That said, it’s ...
Draper took to X, sharing his recent interview on the Founders Room Podcast, in which he talked about the increasing dominance of Bitcoin in the blockchain space. “I think there’s a gravitational pull ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. The meeting was conducted with U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results